Peptides Similar to Setmelanotide (IMCIVREE)
Compare Setmelanotide (IMCIVREE) with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Afamelanotide: High - Both are synthetic melanocortin receptor agonists derived from alpha-MSH, though they target different clinical applications
- •Semaglutide: Low - Both are injectable peptides approved for weight management, but they work through entirely different mechanisms
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Setmelanotide (IMCIVREE) (current) | - | - |
| Afamelanotide | High - Both are synthetic melanocortin receptor agonists derived from alpha-MSH, though they target different clinical applications | Afamelanotide primarily targets MC1R for skin photoprotection (erythropoietic protoporphyria), while setmelanotide primarily targets MC4R for appetite regulation. Different receptor selectivity profiles despite structural similarities. |
| Semaglutide | Low - Both are injectable peptides approved for weight management, but they work through entirely different mechanisms | Semaglutide is a GLP-1 receptor agonist for common obesity and T2D, while setmelanotide is an MC4R agonist for rare genetic obesity. Different mechanisms, different patient populations, different clinical contexts. |
AfamelanotideHigh - Both are synthetic melanocortin receptor agonists derived from alpha-MSH, though they target different clinical applications
Differences
Afamelanotide primarily targets MC1R for skin photoprotection (erythropoietic protoporphyria), while setmelanotide primarily targets MC4R for appetite regulation. Different receptor selectivity profiles despite structural similarities.
Advantages
Setmelanotide has higher MC4R selectivity for appetite/weight regulation; FDA-approved for genetic obesity with demonstrated dramatic weight loss in target populations
Disadvantages
Setmelanotide has narrower indications (rare genetic obesity only); causes sexual adverse events and requires REMS distribution
SemaglutideLow - Both are injectable peptides approved for weight management, but they work through entirely different mechanisms
Differences
Semaglutide is a GLP-1 receptor agonist for common obesity and T2D, while setmelanotide is an MC4R agonist for rare genetic obesity. Different mechanisms, different patient populations, different clinical contexts.
Advantages
Semaglutide is approved for common obesity affecting millions, weekly dosing, oral formulation available, proven CV benefit, and far larger evidence base
Disadvantages
Semaglutide does not address MC4R pathway deficiency; may not be effective in patients with monogenic MC4R pathway obesity where setmelanotide is specifically indicated
Peptides Related to Setmelanotide#
Setmelanotide (IMCIVREE) occupies a unique niche as the only approved MC4R agonist for genetic obesity. Its closest structural relatives are other melanocortin peptides, while its therapeutic comparators are other obesity treatments used in different clinical contexts.
Afamelanotide (Scenesse)#
Afamelanotide is the most structurally related approved melanocortin peptide. Both are synthetic analogs derived from the natural alpha-melanocyte-stimulating hormone (alpha-MSH), but they differ in receptor selectivity and clinical application. Afamelanotide primarily activates MC1R for skin photoprotection in erythropoietic protoporphyria (EPP), while setmelanotide is optimized for MC4R activation in the hypothalamus for appetite regulation. Both cause skin hyperpigmentation as a pharmacological effect.
Semaglutide (Ozempic / Wegovy)#
Semaglutide represents the dominant approach to pharmacological obesity treatment through GLP-1 receptor agonism. While both setmelanotide and semaglutide address obesity, they serve entirely different patient populations and work through distinct mechanisms. Setmelanotide is specifically designed for the extremely rare cases of monogenic obesity where the MC4R pathway is disrupted, while semaglutide addresses the much larger population with common polygenic obesity.
Summary Comparison#
| Feature | Setmelanotide | Afamelanotide | Semaglutide |
|---|---|---|---|
| Primary receptor | MC4R | MC1R | GLP-1R |
| Indication | Genetic obesity | EPP (photoprotection) | Common obesity, T2D |
| Mechanism | Appetite/satiety | Melanin production | Insulin/satiety/GI |
| Patient population | Ultra-rare | Rare | Very large |
| Dosing | Daily SC | Bimonthly implant | Weekly SC or daily oral |
| Weight loss | ~25% (in target pop.) | Not primary goal | 15-20% |
| Regulatory status | Approved (2020) | Approved (2019) | Approved |
Comparison Context#
Setmelanotide (IMCIVREE) belongs to the Metabolic category of research peptides. Comparing Setmelanotide (IMCIVREE) with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Setmelanotide (IMCIVREE) in mechanism, indication, or therapeutic category:
Setmelanotide (IMCIVREE) vs Afamelanotide#
Similarity: High - Both are synthetic melanocortin receptor agonists derived from alpha-MSH, though they target different clinical applications
Key Differences: Afamelanotide primarily targets MC1R for skin photoprotection (erythropoietic protoporphyria), while setmelanotide primarily targets MC4R for appetite regulation. Different receptor selectivity profiles despite structural similarities.
Advantages of Afamelanotide: Setmelanotide has higher MC4R selectivity for appetite/weight regulation; FDA-approved for genetic obesity with demonstrated dramatic weight loss in target populations
Disadvantages of Afamelanotide: Setmelanotide has narrower indications (rare genetic obesity only); causes sexual adverse events and requires REMS distribution
Researchers choosing between Setmelanotide (IMCIVREE) and Afamelanotide should consider the development stage, available evidence, and specific research objectives when making their selection.
Setmelanotide (IMCIVREE) vs Semaglutide#
Similarity: Low - Both are injectable peptides approved for weight management, but they work through entirely different mechanisms
Key Differences: Semaglutide is a GLP-1 receptor agonist for common obesity and T2D, while setmelanotide is an MC4R agonist for rare genetic obesity. Different mechanisms, different patient populations, different clinical contexts.
Advantages of Semaglutide: Semaglutide is approved for common obesity affecting millions, weekly dosing, oral formulation available, proven CV benefit, and far larger evidence base
Disadvantages of Semaglutide: Semaglutide does not address MC4R pathway deficiency; may not be effective in patients with monogenic MC4R pathway obesity where setmelanotide is specifically indicated
Researchers choosing between Setmelanotide (IMCIVREE) and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Setmelanotide (IMCIVREE)
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer